“Advancing our clinical programs with the goal of changing the treatment landscape in mental health has always been Cybin’s mission,” said Doug Drysdale, Chief Executive Officer of Cybin. “We have made enormous progress during the past quarter, with ample momentum to carry us through year-end and into 2024. We are actively gathering important data from CYB003, our deuterated psilocybin analog program, and CYB004 and SPL028, our deuterated DMT programs, with topline readouts expected before the end of 2023. As a company, we are proud of our consistent progress, robust patent portfolio, skilled and dedicated team of drug development experts, and believe we are well-positioned to progress our pipeline toward potential regulatory approval.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYBN:
- Cybin, Inc. (CYBN) Q2 Earnings Cheat Sheet
- Cybin’s depressive disorder candidate meets Phase 2 efficacy endpoint
- Cybin reports CYB003 demonstrated reduction in symptoms of depression
- Cybin announces grant of two US patents protecting deuterated DMT program
- Cybin completes dosing in final cohort of CYB003 trial